Please ensure Javascript is enabled for purposes of website accessibility

Here's Why LivaNova Rose as Much as 13% Today

By Maxx Chatsko - May 31, 2018 at 3:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the company's most promising growth products might soon be covered by Medicare.

What happened

Shares of medical device developer LivaNova (LIVN -2.07%) jumped 13% today after the company commented on the U.S. Centers for Medicare & Medicaid Services (CMS) reconsideration of whether or not to cover the technology provider's Vagus Nerve Stimulation Therapy (VNS Therapy) for treatment-resistant depression (TRD).

That's a mouthful of acronyms, but today's development can be distilled down pretty simply: One of the company's best-selling products may be eligible to be covered by Medicare in the near future. It would mark the first time in over 10 years that VNS Therapy for TRD would be covered by Medicare, which could significantly expand the product's market opportunity.

As of 12:43 p.m. EDT, the stock had settled to a 12.4% gain.

A cartoon showing growth of a bar chart, with the last column represented by a red arrow pointing up and sitting on a spring board.

Image source: Getty Images.

So what

LivaNova is a $4.5 billion healthcare company that develops medical devices for cardiac surgery and neuromodulation. The company reported $250 million in total revenue in the first quarter of 2018, including $156 million from its cardiac surgery segment and $94 million from its neuromodulation segment.

The former segment is mostly driven by sales of cardiopulmonary machines used during surgery and heart valves inserted into patients. The latter is comprised almost entirely of sales of the VNS Therapy system to treat seizures, but is also approved for TRD. The device is similar to a pacemaker and sends electric pulses to the vagus nerve to help control various brain functions that may be misfiring.

If CMS decides to cover the medical technology for TRD, then it could open up an important new market for LivaNova, which played a central role in asking CMS to reconsider its decision of non-coverage.

Now what

While there's still a long way to go before CMS finalizes a decision and puts a process in place for covering VNS Therapy for TRD with Medicare, today's news marks an important step forward for patients and the company. There will be a 30-day comment period and then several months of discussions with all stakeholders. But in a best case scenario, LivaNova shareholders and TRD patients might know whether or not CMS's coverage policy will change by the end of 2018.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

LivaNova PLC Stock Quote
LivaNova PLC
LIVN
$61.99 (-2.07%) $-1.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.